Literature DB >> 8229794

The role of the kidney in canine blood pressure control: direct assessment of the closed-loop gain.

P B Persson1, H Ehmke, H R Kirchheim, M Lempinen, B Nafz.   

Abstract

1. The feedback control of arterial blood pressure by the kidney in the range of hours was investigated in resting, conscious foxhounds. 2. A servo-control device (connected to an aortic occlusive cuff implanted above both renal arteries) was used to maintain a constant pressure difference of 20 mmHg between aortic pressure measured proximal (mean arterial blood pressure: MAP) and distal (renal artery pressure: RAP) to the aortic cuff. 3. Protocol 1 (n = 6) served as a 4 h time control without intervention, protocol 2 (n = 6) consisted of three periods: after a control of 20 min duration, the servo-control device was activated for 180 min; this was followed by a recovery period of 40 min. Protocol 3 (n = 6) was as protocol 2, but during converting-enzyme inhibition. 4. Servo-control increased plasma renin activity (PRA) transiently from 0.5 ng angiotensin I (AI) ml-1 h-1 to a peak value of 2.4 ng AI ml-1 h-1, subsequently both RAP and MAP rose to reach a new steady state. During this increase in RAP, PRA declined to 1.4 ng AI ml-1 h-1. 5. On average, the compensation of the pressure decrease sensed by the kidney amounted to 63% of the error signal (closed-loop gain of 0.63 +/- 0.1). 6. Converting-enzyme inhibition reduced this closed-loop gain significantly (protocol 2 vs. protocol 3, 0.63 +/- 0.1 vs. 0.15 +/- 0.1; P < 0.05). 7. It is concluded, that the kidney plays an important role in medium-term blood pressure regulation, most probably via the renin-angiotensin system.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8229794      PMCID: PMC1175377          DOI: 10.1113/jphysiol.1993.sp019626

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  20 in total

Review 1.  Role of the renin-angiotensin system in control of sodium excretion and arterial pressure.

Authors:  J E Hall; A C Guyton; H L Mizelle
Journal:  Acta Physiol Scand Suppl       Date:  1990

2.  Identification of major slow blood pressure oscillations in conscious dogs.

Authors:  P B Persson; H Ehmke; W W Köhler; H R Kirchheim
Journal:  Am J Physiol       Date:  1990-10

Review 3.  Blood pressure control--special role of the kidneys and body fluids.

Authors:  A C Guyton
Journal:  Science       Date:  1991-06-28       Impact factor: 47.728

4.  Modulation of natriuresis by sympathetic nerves and angiotensin II in conscious dogs.

Authors:  P B Persson; H Ehmke; U Kögler; H Kirchheim
Journal:  Am J Physiol       Date:  1989-03

5.  Sympathetic modulation of renal autoregulation by carotid occlusion in conscious dogs.

Authors:  P B Persson; H Ehmke; B Nafz; H R Kirchheim
Journal:  Am J Physiol       Date:  1990-02

6.  Pressure natriuresis and control of arterial pressure during chronic norepinephrine infusion.

Authors:  J E Hall; H L Mizelle; L L Woods; J P Montani
Journal:  J Hypertens       Date:  1988-09       Impact factor: 4.844

Review 7.  Control strategies in physiological systems.

Authors:  J C Houk
Journal:  FASEB J       Date:  1988-02       Impact factor: 5.191

8.  Autoregulation of renal blood flow, glomerular filtration rate and renin release in conscious dogs.

Authors:  H R Kirchheim; H Ehmke; E Hackenthal; W Löwe; P Persson
Journal:  Pflugers Arch       Date:  1987-11       Impact factor: 3.657

9.  Control of arterial pressure and renal function during chronic renin inhibition.

Authors:  J E Hall; H L Mizelle
Journal:  J Hypertens       Date:  1990-04       Impact factor: 4.844

Review 10.  Regulation of arterial pressure: role of pressure natriuresis and diuresis.

Authors:  J E Hall; A C Guyton; T G Coleman; H L Mizelle; L L Woods
Journal:  Fed Proc       Date:  1986-12
View more
  1 in total

1.  Buffering of blood pressure variability by the renin-angiotensin system in the conscious dog.

Authors:  A Just; H R Kirchheim; H Ehmke
Journal:  J Physiol       Date:  1998-10-15       Impact factor: 5.182

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.